Zhejiang Cancer Hospital
🇨🇳China
Clinical Trials
253
Active:7
Completed:35
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:18
Phase 2:123
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (214 trials with phase data)• Click on a phase to view related trials
Phase 2
123 (57.5%)Not Applicable
45 (21.0%)Phase 3
19 (8.9%)Phase 1
18 (8.4%)Phase 4
7 (3.3%)Early Phase 1
2 (0.9%)An in Vivo CT Imaging Study of GMA-Tulip, I-gel, and LMA Supreme (GLAM-II)
Not Applicable
Recruiting
- Conditions
- Supraglottic Airway Device
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT07196696
- Locations
- 🇨🇳
Jiangling Wang, Hangzhou, Zhejiang, China
A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast Cancer
Not yet recruiting
- Conditions
- Breast Cancer Females
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT07180914
Study on Safety and Efficacy of UCB-MNCs for Radiation-induced Lung Injury
Not Applicable
Not yet recruiting
- Conditions
- Radiation-induced Lung Injury
- Interventions
- Biological: UCB-MNCs
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT07177456
Study on Safety and Efficacy of UCB-MNCs for Chronic Radiation Enteritis
Not Applicable
Not yet recruiting
- Conditions
- Chronic Radiation Induced Intestinal InjuryChronic Radiation Enteritis
- Interventions
- Biological: UCB-MNCs
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT07175207
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
Not Applicable
Not yet recruiting
- Conditions
- Rectal CancerRadiationAK112
- Interventions
- Radiation: radiotherapyDrug: Ivonescimab (20mg/kg Q3W)Other: Non-operative ManagementProcedure: Surgery
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT07162714
- Prev
- 1
- 2
- 3
- 4
- 5
- 50
- Next
News
Fapon Biopharma Enrolls First Patient in Phase I Trial of FP008, Novel Anti-PD-1 Fusion Protein for Solid Tumors
Fapon Biopharma has enrolled the first patient in China for its Phase I clinical trial of FP008, a first-in-class anti-PD-1 × IL-10M fusion protein immunotherapy for advanced solid tumors.